Boston Scientific Corp (MIL:1BSX)
€ 85.5 0 (0%) Market Cap: 126.98 Bil Enterprise Value: 135.61 Bil PE Ratio: 74.26 PB Ratio: 6.39 GF Score: 56/100

Boston Scientific Corp at JPMorgan Healthcare Conference Transcript

Jan 14, 2020 / 04:00PM GMT
Robert Justin Marcus
JP Morgan Chase & Co, Research Division - Analyst

Good morning, everyone. I'm Robbie Marcus, the medical device analyst here at JPMorgan. I'm very happy to kick off the medical device track for day 2 of the conference. Happy to introduce Mike Mahoney, Chairman and CEO of Boston Scientific. Mike?

Michael F. Mahoney
Boston Scientific Corporation - Chairman, President & CEO

Thanks, Robbie. Good morning, everyone. I forgot my clicker. Good morning, everyone. Thank you for your interest in Boston Scientific and for being here bright and early in the morning. And we look forward to sharing with you the exciting future that this company has and we'll try to do this in 25 minutes this year.

Here are our safe harbor and forward-looking statements that I won't read through but you can see. And also, the IR team has done a nice job of laying out our regulatory disclaimers and we have this pretty comprehensive deck that you'll see in the webcast materials. And also, many of you may have seen that we did announce fourth quarter sales

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot